Status:

COMPLETED

A Safety Study of Sacubitril/Valsartan in Japanese Pediatric Patients With Heart Failure Due to Systemic Left Ventricle Systolic Dysfunction Who Have Completed CLCZ696B2319E1 Study

Lead Sponsor:

Novartis Pharmaceuticals

Conditions:

Heart Failure

Eligibility:

All Genders

3-18 years

Phase:

PHASE3

Brief Summary

The purpose of this open-label study was to collect additional safety information of sacubitril/valsartan and to provide post-trial access to sacubitril/valsartan for the eligible Japanese patients wh...

Detailed Description

This trial (CLCZ696B2319E2) was a multicenter, open-label extension study for Japanese patients who have successfully completed the CLCZ696B2319E1 study. Only Japanese patients who successfully comple...

Eligibility Criteria

Inclusion

  • Signed informed consent
  • \<18 years of age (at the time of signing informed consent)
  • Completed CLCZ696B2319E1 study and safely enrolled

Exclusion

  • Permanently discontinued the study treatment during CLCZ696B2319E1 study
  • Renal vascular hypertension (including renal artery stenosis)
  • History of angioedema
  • Having parents or legal guardians who do not give consent or allow the child to give assent, or inability of patient or the parents/legal guardians to follow instructions or comply with follow-up procedures
  • Any medical condition(s) that may put the patient at risk in the Investigator's opinion or that the Investigator deems unsuitable for the study

Key Trial Info

Start Date :

December 4 2023

Trial Type :

INTERVENTIONAL

Allocation :

ACTUAL

End Date :

August 14 2024

Estimated Enrollment :

8 Patients enrolled

Trial Details

Trial ID

NCT06149104

Start Date

December 4 2023

End Date

August 14 2024

Last Update

October 14 2025

Active Locations (6)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 2 (6 locations)

1

Novartis Investigative Site

Ōbu, Aichi-ken, Japan, 474 8710

2

Novartis Investigative Site

Ōmura, Nagasaki, Japan, 856-8562

3

Novartis Investigative Site

Bunkyo Ku, Tokyo, Japan, 113 8655

4

Novartis Investigative Site

Setagaya-ku, Tokyo, Japan, 157-8535

A Safety Study of Sacubitril/Valsartan in Japanese Pediatric Patients With Heart Failure Due to Systemic Left Ventricle Systolic Dysfunction Who Have Completed CLCZ696B2319E1 Study | DecenTrialz